Hepatitis b cure attempt falls short: study terminated early
NCT ID NCT05345990
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tested whether giving hepatitis B antibodies (HBIG) could clear the hepatitis B surface antigen (HBsAg) in people with chronic hepatitis B. It included 13 adults who had been on antiviral therapy for at least a year. The treatment was given for 12 weeks, but the study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hannover Medical School, Department for Gastroenterology, Hepatology and Endocrinology
Hanover, Lower Saxony, 30625, Germany
Conditions
Explore the condition pages connected to this study.